ArticleBlood2024

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.

Wallace Bourgeois et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.